Results 261 to 270 of about 191,466 (342)

Clioquinol as a new therapy in epilepsy: From preclinical evidence to a proof‐of‐concept clinical study

Epilepsia, EarlyView.
Abstract Objective Drug‐resistant epilepsy (DRE) affects >25 million people worldwide and is often associated with neuroinflammation. Increasing evidence links deficiency or malfunctioning of the enzyme phosphoglycerate dehydrogenase (PHGDH), which converts 3‐phosphoglycerate to generate serine and the neurotransmitter glycine, with (drug‐resistant ...
Karin Thevissen, Annelii Ny, Daniëlle Copmans, Jana Tits, Kenichi Kamata, Eva Gielis, Kevin Longin, Jo Sourbron, Peravina Thergarajan, Tracie Huey‐Lin Tan, Idrish Ali, Nigel C. Jones, Terence J. O'Brien, Mastura Monif, Bridgette D. Semple, Christine Germeys, Benedetta Frizzi, Virginia Minniti, Sebastian Perrone, Carole L. Linster, Ilaria Elia, Ludo Van Den Bosch, Bruno P. A. Cammue, Arnout Voet, Lieven Lagae, Peter de Witte   +25 more
wiley   +1 more source

Mitochondrial Complex I and ROS control neuromuscular function through opposing pre- and postsynaptic mechanisms. [PDF]

PLoS Biol
Mallik B, Bhat SA, Wang X, Frank CA.
europepmc   +1 more source

Nefiracetam induces an LTP-like facilitation of hippocampal neurotransmission as a result of modulation of nicotinic ACh receptors

, 2000
Shigeo Watabe, Tomoyuki Nishizaki, Mitsunobu Yoshii   +2 more
openalex   +1 more source

WONOEP XVII appraisal: Targeting network excitability beyond the synapse ‐Neurotransmitter, ionic, and electro ‐diffusions

Epilepsia, EarlyView.
Abstract Epilepsy affects approximately 1% of the population worldwide, and although medications are effective in the majority of cases, seizures persist in approximately 30% of patients. Despite the effort to develop new antiseizure drugs, the rate of pharmacoresistance in patients has not diminished over the past 3 decades. There is thus a real unmet
Vincent Magloire, Marco de Curtis, Jeffrey Noebels, Gilles Huberfeld, Piotr Suffczynski, Vadym Gnatkovsky, Olga Tyurikova, Dominique Durand, David C. Henshall, Cian McCafferty   +9 more
wiley   +1 more source

Serotonergic Modulators in Alzheimer's Disease: A Hope in the Hopeless Condition. [PDF]

Chem Biodivers
Almohmadi NH, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Fakhry MM, Alexiou A, Papadakis M, Batiha GE.   +7 more
europepmc   +1 more source

Effect of the AT1-Receptor Antagonists Losartan, Irbesartan, and Telmisartan on Angiotensin II-Induced Facilitation of Sympathetic Neurotransmission in the Rat Mesenteric Artery

, 2001
Jippe C. Balt, Marie-Jeanne Mathy, Alexander Nap, Martin Pfaffendorf, Pieter A. van Zwieten   +4 more
openalex   +1 more source

Electrical stimulation of stem cell–derived human neural networks for evaluating anti‐seizure medications

Epilepsia, EarlyView.
Abstract Objective Current preclinical epilepsy drug screening relies on animal models that poorly reflect human neurophysiology, leading to high failure rates in clinical translation. We aimed to establish a human in vitro model using human‐induced pluripotent stem cell (hiPSC)–derived cortical neurons cultured on multielectrode arrays (MEAs), capable
Joshua Nicholls, Jinchao Gu, Zhibin Chen, Zikou Liu, Ana Antonic‐Baker, Muhammad Shahid Javaid, Eliza Moore, Hailin Zhu, Afaf Altalhi, David K. Wright, Huseyin Sumer, Terence J. O'Brien, Patrick Kwan, Ben Rollo   +13 more
wiley   +1 more source

Neurobiological Pathways Linking Compulsive Sexual Behavior Disorder and Psychiatric Comorbidities: A Narrative Review. [PDF]

Cureus
Puszcz A, Górski J, Pierudzka W.
europepmc   +1 more source

Drug discovery and preclinical testing of drug candidates for developmental and epileptic encephalopathies

Epilepsia, EarlyView.
Abstract Drug development for developmental and epileptic encephalopathies (DEEs) follows different strategies on one hand including disease‐targeting precision medicine approaches considering the genetic variants and pathomechanisms in DEEs and on the other hand including therapeutic approaches with novel targets or second‐generation drug candidates ...
Heidrun Potschka, Daniel Pérez‐Pérez
wiley   +1 more source

Nigrostriatal dopaminergic neurotransmission and resilience to peripheral systemic risk factors for gait slowing upon transition to uneven surfaces in older adult. [PDF]

Aging Brain
Chahine LM, Rosso A, Troidl I, Ganguli M, Newman A, Cummings S, Studenski S, Lopresti B, Royse S, Huppert T, Redfern M, Sparto PJ, Bohnen NI, Rosano C.   +13 more
europepmc   +1 more source